2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
W

2020 ASCO Update on mCRPC: Is 177Lu-PSMA-617 Superior PSA Response Rate vs. Cabazitaxel Practice Changing?

By 2020 ASCO Virtual Direct™ Highlights FEATURING William Kelly
By 2020 ASCO Virtual Direct™ Highlights FEATURING William Kelly
84 views
July 15, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

17:33
AstraZeneca Oncology

First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…

Feat. S. Lewin

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam
GU
13:29
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Diagnostic/Prognostic Testing in PC: Is 68Ga- PS…

Feat. W. Kelly
05:17
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mCRPC: Is 177Lu-PSMA-617 Superior PSA Response R…

Feat. W. Kelly
10:14
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Prostate Cancer: Is Testosterone Suppre…

Feat. W. Kelly
17:12
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mUC: Does Switch Maintenance Avelumab + BSC Prol…

Feat. J. Kim
08:55
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: Pembrolizumab + Axitinib vs. Sunit…

Feat. J. Kim
07:08
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: Efficacy and Safety Analysis of Ni…

Feat. J. Kim